NA
DGX icon

Navellier & Associates’s Quest Diagnostics DGX Stock Holding History

Navellier & Associates’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,660
Closed -$505K – 347
2023
Q4 		$505K Buy
3,660
+904
+33% +$119K 0.08% 221
2023
Q3 		$336K Buy
2,756
+217
+9% +$28.9K 0.06% 246
2023
Q2 		$357K Buy
2,539
+412
+19% +$56.8K 0.07% 207
2023
Q1 		$301K Buy
2,127
+116
+6% +$16.6K 0.06% 220
2022
Q4 		$315K Sell
2,011
-9
-0.4% -$1.29K 0.06% 211
2022
Q3 		$248K Sell
2,020
-34
-2% -$4.48K 0.06% 235
2022
Q2 		$273K Hold
2,054
– – 0.06% 241
2022
Q1 		$281K Buy
2,054
+53
+3% +$7.39K 0.05% 256
2021
Q4 		$346K Sell
2,001
-7
-0.3% -$1.06K 0.05% 252
2021
Q3 		$292K Hold
2,008
– – 0.04% 266
2021
Q2 		$265K Sell
2,008
-11
-0.5% -$1.44K 0.04% 256
2021
Q1 		$259K Sell
2,019
-12
-0.6% -$1.48K 0.05% 250
2020
Q4 		$242K Buy
+2,031
New +$248K 0.04% 249

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $23.3B AUM 26.95% 1-Year Est. Return
Grantham, Mayo, Van Otterloo & Co (GMO)
Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $44.4B AUM 36.05% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Navellier & Associates's DGX Position: Q1 2024 in Review

Navellier & Associates sold out of Quest Diagnostics (DGX) in Q1 2024, closing a stake of 3,660 shares — an estimated $505K sold.

Navellier & Associates first reported a position in DGX in Q4 2020 and held it in 13 quarters. The position peaked at $505K in Q4 2023. 819 funds tracked by Wall St. Rank hold DGX as of Q1 2024.

  • Navellier & Associates reported no remaining Quest Diagnostics position as of Q1 2024 after selling out during the quarter.
  • Navellier & Associates sold 3,660 Quest Diagnostics shares in Q1 2024, an estimated $505K.
  • Navellier & Associates first reported a position in Quest Diagnostics in Q4 2020 and held it in 13 quarters.
  • Navellier & Associates's Quest Diagnostics position peaked at $505K in Q4 2023.
  • 819 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2024.

Based on Navellier & Associates's 13F filing for Q1 2024, filed 14 May 2024.